Overview
Background
I am working as part of an academic team on a project aimed at completing a Phase 1 Clinical Trial using pluripotent stem cell derived cardiomyocytes for the treatment of “no-option” end stage heart failure. My primary role in the team is the development of a scalable bioreactor based process for the produciton of pluripotent stem cell derived cardiomyocytes. This process has been developed to meet GMP and local regulatory requirements. Ancilliary to this, I have been wokring on the development and validation of safety assays in line with ICH guidelines for the clinical trial.
Availability
- Dr Steve Dingwall is:
- Available for supervision
Research impacts
Coronary heart disease is the leading cause of death in Australia, representing one in five deaths and accounting for approximately 443 hospitalizations per day. Heart failure costs Australia approximately $1 billion per annum. Following myocardial infarction (a heart attack) it is estimated that approximately 1 billion heart cells are lost. The loss of this heart muscle results in a decreased capacity for the heart to effectively pump blood through the body. Several clinical trials internationally have attempted to restore heart function using non cardiac cell types including skeletal myoblasts, bone marrow derived cells and mesenchymal stem cells. However, these clinical trials have yielded minimal improvements. Our team aims to be the first in Australia to try to replace this lost tissue with the very cell type that is lost following a heart attack (cardiomyocytes). These cardiomyocytes are produced from induced pluripotent stem cells, through a process with the potential to yield the high number of cells required to replace the lost tissue. Preclinical data from our team and others internationally indicates a strong potential for this therapy.
Works
Search Professor Steve Dingwall’s works on UQ eSpace
2024
Journal Article
Analysis of three characterization assays reveals ddPCR of LIN28A as the most sensitive for the detection of residual pluripotent stem cells in cellular therapy products
Sun, Jinda, Yates, Clarissa, Dingwall, Steve, Ongtengco, Cherica, Power, Dominique, Gray, Peter and Prowse, Andrew (2024). Analysis of three characterization assays reveals ddPCR of LIN28A as the most sensitive for the detection of residual pluripotent stem cells in cellular therapy products. Cytotherapy, 26 (11), 1374-1381. doi: 10.1016/j.jcyt.2024.05.019
2024
Conference Publication
Production of induced pluripotent stem cell derived cardiomyocytes in a scalable vertical wheel bioreactor system
Dingwall, S., Ongtenco, C., Sun, J., Power, D., Gray, P. and Prowse, A. (2024). Production of induced pluripotent stem cell derived cardiomyocytes in a scalable vertical wheel bioreactor system. 30th Annual ISCT Meeting, Vancouver, Canada, 29 May - 1 June 2024. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jcyt.2024.03.453
2024
Journal Article
Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias
Selvakumar, Dinesh, Clayton, Zoe E., Prowse, Andrew, Dingwall, Steve, Kim, Sul Ki, Reyes, Leila, George, Jacob, Shah, Haisam, Chen, Siqi, Leung, Halina H. L., Hume, Robert D., Tjahjadi, Laurentius, Igoor, Sindhu, Skelton, Rhys J. P., Hing, Alfred, Paterson, Hugh, Foster, Sheryl L., Pearson, Lachlan, Wilkie, Emma, Marcus, Alan D., Jeyaprakash, Prajith, Wu, Zhixuan, Chiu, Han Shen, Ongtengco, Cherica Felize J., Mulay, Onkar, McArthur, Jeffrey R., Barry, Tony, Lu, Juntang, Tran, Vu ... Chong, James J. H. (2024). Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias. Nature Cardiovascular Research, 3 (2), 145-165. doi: 10.1038/s44161-023-00419-3
2022
Conference Publication
Cellular heterogeneity of pluripotent stem cell derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias
Selvakumar, D., Clayton, Z., Prowse, A., Dingwall, S., George, J., Shah, H., Paterson, H., Jeyaprakesh, P., Wu, Z., Campbell, T., Kotake, Y., Turnbull, S., Nguyen, Q., Grieve, S., Palpant, N., Pathan, F., Kizana, E., Kumar, S., Gray, P. and Chong, J. (2022). Cellular heterogeneity of pluripotent stem cell derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias. 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Gold Coast, QLD Australia, 11-14 August 2022. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2022.06.004
2016
Journal Article
Rats with a missense mutation in Atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage
Quek, Hazel, Luff, John, Cheung, KaGeen, Kozlov, Sergei, Gatei, Magtouf, Lee, C. Soon, Bellingham, Mark C., Noakes, Peter G., Lim, Yi Chieh, Barnett, Nigel L., Dingwall, Steven, Wolvetang, Ernst, Mashimo, Tomoji, Roberts, Tara L. and Lavin, Martin F. (2016). Rats with a missense mutation in Atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage. Journal of Leukocyte Biology, 101 (4), 927-947. doi: 10.1189/jlb.4VMA0716-316R
2016
Journal Article
A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype
Quek, Hazel, Luff, John, Cheung, KaGeen, Kozlov, Sergei, Gatei, Magtouf, Lee, C Soon, Bellingham, Mark C., Noakes, Peter G., Lim, Yi Chieh, Barnett, Nigel L., Dingwall, Steven, Wolvetang, Ernst, Mashimo, Tomoji, Roberts, Tara L. and Lavin, Martin F. (2016). A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype. Human Molecular Genetics, 26 (1), 109-123. doi: 10.1093/hmg/ddw371
2016
Other Outputs
Stem Cell Therapies and Radiological Imaging in Ataxia Telangiectasia
Dingwall, Steven (2016). Stem Cell Therapies and Radiological Imaging in Ataxia Telangiectasia. PhD Thesis, School of Medicine, The University of Queensland. doi: 10.14264/uql.2016.822
2016
Conference Publication
Neuroinflammation drives the neuronal degenerative phenotype in a rat model of Ataxia-telangiectasia
Quek, H., Luff, J., Cheung, K., Kozlov, S., Gatei, M., Lee, C. S., Bellingham, M., Noakes, P., Lim, Y. C., Barnett, N., Dingwall, S., Wolvetang, E., Mashimo, T., Roberts, T. and Lavin, M. (2016). Neuroinflammation drives the neuronal degenerative phenotype in a rat model of Ataxia-telangiectasia. International Congress of Immunology (ICI), Melbourne, Australia, Aug 21-26, 2016. Weinheim, Germany: Wiley - V C H Verlag GmbH & Co. KGaA. doi: 10.1002/eji.201670200
2015
Journal Article
Neoplastic human embryonic stem cells as a model of radiation resistance of human cancer stem cells
Dingwall, Steve, Lee, Jung Bok, Guezguez, Borhane, Fiebig, Aline, McNicol, Jamie, Boreham, Douglas, Collins, Tony J. and Bhatia, Mick (2015). Neoplastic human embryonic stem cells as a model of radiation resistance of human cancer stem cells. Oncotarget, 6 (26), 22258-22269. doi: 10.18632/oncotarget.4165
2015
Journal Article
Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations
Salci, Kyle R., Lee, Jong-Hee, Laronde, Sarah, Dingwall, Steve, Kushwah, Rahul, Fiebig-Comyn, Aline, Leber, Brian, Foley, Ronan, Dal Cin, Arianna and Bhatia, Mickie (2015). Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations. Stem Cells, 33 (6), 1839-49. doi: 10.1002/stem.1994
2015
Journal Article
Expression of Histocompatibility 2 Blastocyst (H2-Bl) in embryonic stem cells inhibits CD8+ T-cell activation but is not sufficient to facilitate graft tolerance
Dingwall, Steven, Brooks, Andrew, Apte, Simon H., Waters, Mike, Lavin, Martin F. and Wolvetang, Ernst J. (2015). Expression of Histocompatibility 2 Blastocyst (H2-Bl) in embryonic stem cells inhibits CD8+ T-cell activation but is not sufficient to facilitate graft tolerance. Journal of Stem Cell Research and Therapy, 5 (12) 1000320, 1-8. doi: 10.4172/2157-7633.1000320
2011
Journal Article
Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease
Risueño, Ruth M, Campbell, Clinton J V, Dingwall, Steve, Levadoux-Martin, Marilyne, Leber, Brian, Xenocostas, Anargyros and Bhatia, Mickie (2011). Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood, 117 (26), 7112-7120. doi: 10.1182/blood-2011-01-329078
2011
Journal Article
Human health and the biological effects of tritium in drinking water: Prudent policy through science - Addressing the ODWAC new recommendation
Dingwall, S., Mills, C. E., Phan, N., Taylor, K. and Boreham, D. R. (2011). Human health and the biological effects of tritium in drinking water: Prudent policy through science - Addressing the ODWAC new recommendation. Dose-Response, 9 (1), 6-31. doi: 10.2203/dose-response.10-048.Boreham
2009
Journal Article
Characterization of human embryonic stem cells with features of neoplastic progression
Werbowetski-Ogilvie, Tamra E, Bossé, Marc, Stewart, Morag, Schnerch, Angelique, Ramos-Mejia, Veronica, Rouleau, Anne, Wynder, Tracy, Smith, Mary-Jo, Dingwall, Steve, Carter, Tim, Williams, Christopher, Harris, Charles, Dolling, Joanna, Wynder, Christopher, Boreham, Doug and Bhatia, Mickie (2009). Characterization of human embryonic stem cells with features of neoplastic progression. Nature Biotechnology, 27 (1), 91-7. doi: 10.1038/nbt.1516
Funding
Current funding
Supervision
Availability
- Dr Steve Dingwall is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Steve Dingwall's areas of expertise, story ideas and help finding experts, contact our Media team: